Stuart Crow – Non Executive Chairman – Lake Resources N.L. (ASX:LKE, OTC: LLKKF) is a responsible lithium developer utilising state of-the-art ion exchange extraction technology for production of sustainable, high purity lithium from its flagship Kachi Project in Catamarca Province within the Lithium Triangle in Argentina. Lake also has three additional early-stage projects in this region.
Copyright 2024 – Finance News Network
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
29 07 2024 - Neil McIntyre - CEO - Diatreme Resources (ASX:DRX) is an emerging Australian producer of mineral and silica sands based in Brisbane. Our key projects comprise the Northern Silica Project and Galalar Silica Sand Project in Far North Queensland, located next to the world's biggest silica sand mine at Cape Flattery.
13 Sep 2024 - Control Bionics Limited (ASX:CBL) CEO Jeremy Steele provides an overview of the company, discussing its suite of augmentative and alternative communication products.
02 Jun 2022 - BluGlass Limited (ASX:BLG) Executive Chair James Walker provides an update on the company, discussing new staff and developments at BluGlass' manufacturing facility in Silicon Valley.
30 Sep 2020 - Nuheara Limited (ASX:NUH) Managing Director & CEO Justin Miller provides an update on the company's range of innovative audio wearables, changes in its marketing and distribution as a result of COVID19, financial position and outlook.
03 Nov 2022 - Antisense Therapeutics Limited (ASX:ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense's progress, attracting new talent to the company, and what drew Dr Filippis to the role.
17 Aug 2022 - WT Financial Group Limited (ASX:WTL) Founder and Managing Director Keith Cullen discusses the company's indicative results and the future of financial advice.
30 Mar 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.
